Friday, June 22, 2012

Genentech: New breast cancer drug Perjeta improves patient survival


Patients who took combination including Perjeta, also known as pertuzumab, had a 38 percent reduced risk of HER2-positive metastatic breast cancer worsening or of them dying, compared to patients who were given only Herceptin and docetaxel.
Median progression-free survival -- or the length of time during and after treatment when a cancer does not worsen -- was 18.5 months for those taxing Perjeta, compared to 12.4 months for the group without Perjeta.

No comments:

Post a Comment